You are here

References

Found 172 results
2016
Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, et al. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016;60(12):7086-7097.
Gallant JE, Moyle G, Berenguer J, Shalit P, Cao H, Liu Y-, et al. Atazanavir plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial. Curr HIV Res. 2016.
van Lunzen J, Pozniak A, Gatell JM, Antinori A, Klauck I, Serrano O, et al. Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study. J Acquir Immune Defic Syndr. 2016;71(5):538-43.
Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, et al. Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. Antivir Ther (Lond). 2016.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents.: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 2016.; 2016.
Díaz A., Casado J., Dronda F., Gómez-Ayerbe C., Vivancos M., Bañón S., et al. Dolutegravir plus rilpivirine in suppressed heavily pretreated HIV-infected patients. In: 21st International AIDS Conference. Durban, South Africa: International AIDS Society; 2016.
Sterrantino G. Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects. In: 14th European Meeting on HIV and Hepatitis. Rome; 2016.
Calza L, Danese I, Magistrelli E, Colangeli V, Manfredi R, Bon I, et al. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors. HIV Clin Trials. 2016;17(1):38-47.
Arribas JR, Girard P-, Paton N, Winston A, Marcelin A-, Elbirt D, et al. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med. 2016;17(5):358-67.
Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.; 2016.
Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016;3(9):e410-20.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, et al. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: MARCH. Clin Infect Dis. 2016;63(1):122-32.
Maggiolo F, Di Filippo E, Valenti D, Ortega PS, Callegaro A. NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe). J Acquir Immune Defic Syndr. 2016;72(1):46-51.
Paton NI, Stöhr W, Oddershede L, Arenas-Pinto A, Walker S, Sculpher M, et al. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technol Assess. 2016;20(21):1-158.
La Rosa AM, Harrison LJ, Taiwo B, Wallis CL, Zheng L, Kim P, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV. 2016;3(6):e247-58.
Cahn P., Kaplan R., Sax P., Squires K., Molina J., Avihingsanon A., et al. Raltegravir (RAL) 1200 mg once daily (QD) is non-inferior to RAL 400 mg twice daily (BID), in combination with tenofovir/emtricitabine, in treatment-naive HIV-1-infected subjects: week 48 results. In: 21st International AIDS Conference. Durban, South Africa: International AIDS Society; 2016.
Cahn P, Kaplan R., Sax P, Squires K, Molina J-, Avihingsanon A, et al. Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects: Week 48 Results. Durban, South Africa; 2016.
van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, et al. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30(2):251-9.
Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, et al. Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. Antivir Ther (Lond). 2016.
Capetti AF, Sterrantino G, Cossu MV, Orofino G, Barbarini G, De Socio GV, et al. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort. PLoS ONE. 2016;11(10):e0164753.
Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43-52.
Latini A, Fabbiani M, Borghi V, Sterrantino G, Giannetti A, Lorenzini P, et al. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infect Dis. 2016;16(1):401.